140 filings
Page 2 of 7
8-K
57mxb3xqdmq6xt2x p2
14 Jun 16
Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia
12:00am
SC 14D9
ilm68p39cfog83705
10 Jun 16
Tender offer solicitation
12:00am
SC TO-T
v0x925f9xu2i9 hdph
10 Jun 16
Third party tender offer statement
12:00am
8-K
tkz9q6mm
6 Jun 16
Other Events
12:00am
SC14D9C
n1f0nf6td6
1 Jun 16
Written communication relating to third party tender offer
12:00am
SC14D9C
0odtwydr
1 Jun 16
Written communication relating to third party tender offer
12:00am
SC TO-C
ndvk2h9
31 May 16
Information about tender offer
12:00am
SC TO-C
ze3 phs04g
31 May 16
Information about tender offer
12:00am
SC14D9C
v6vc8
31 May 16
Written communication relating to third party tender offer
12:00am
8-K
y2ddr hia16ccalc06
31 May 16
U.S. regulatory submission for VYXEOS planned by end of third quarter 2016
12:00am
DEFA14A
6ckecwbalmeb2
31 May 16
Additional proxy soliciting materials
12:00am
8-K
avmyon3tvbwd2 ik3y
27 Apr 16
Entry into a Material Definitive Agreement
12:00am
8-K
0ecv95wpig42o 4smc
5 Apr 16
Departure of Directors or Certain Officers
12:00am
424B5
ppk7r
24 Mar 16
Prospectus supplement for primary offering
12:00am
8-K
n2mjp
23 Mar 16
Entry into a Material Definitive Agreement
12:00am
S-3MEF
xunyzjk5w
23 Mar 16
Registration of additional securities for an S-3
12:00am
424B5
q51k uxn1p
22 Mar 16
Prospectus supplement for primary offering
12:00am
8-K
70wpud i3tot
21 Mar 16
Celator® Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2015 Financial Results
12:00am